AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01295450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apevinat BC
Description: Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily.
Study NCT01295450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Complex
Description: A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
Study NCT02087631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate
Description: Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
Study NCT00651456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy (Pemetrexed and Cisplatin)
Description: * Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
Study NCT00651456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
Description: * Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Study NCT03209804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hybrid operating techniques
Description: A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
Study NCT03209804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hybrid operating techniques
Description: A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
Study NCT04840810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-plane Axis
Description: In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis.
Study NCT04840810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Out of plane Axis
Description: In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis.
Study NCT01903850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spray cryotherapy
Description: spray cryotherapy
Study NCT00262587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
Study NCT00262587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled sugar powder in a placebo inhaler
Study NCT03124979 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LNCS DBI Sensor
Description: Noninvasive Measurement of SpO2
Study NCT04459390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: realtime PCR
Description: Detection of SARS-CoV-2 genes by realtime PCR
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Intervention drug:~Dose: 500mg tid for 10 days
Study NCT02034799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal Fibrin Sealant
Study NCT02034799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Study NCT01682174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Drink
Study NCT01682174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Drink
Study NCT01682174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Drink
Study NCT01682174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Drink
Study NCT02070848 — intervention group
Intervention type: OTHER
Intervention: Session 1-4
Description: Familiarization sessions to knee-extensor exercise separated by 72h recovery
Study NCT02070848 — intervention group
Intervention type: OTHER
Intervention: Session 4
Description: After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide with guaifenesin
Description: Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan hydrobromide with guaifenesin
Description: Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guaifenesin
Description: Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine Sustained Action
Description: Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine Sustained Action
Description: Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline spray (0.65%)
Description: Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion
Study NCT00377403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray (0.65%)
Description: Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion
Study NCT01746004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2157299
Description: \[\^14C\]-LY2157299 monohydrate administered as oral solution
Study NCT02541890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work place intervention
Description: Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
Study NCT01372306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Study NCT01372306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Study NCT03785561 — intervention group
Intervention type: OTHER
Intervention: participation in a health research study
Description: Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
Study NCT01473667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block (SCP) block
Description: SCP block using 10-15ml of 1% Ropivacaine
Study NCT01473667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local site infiltration
Description: Local site infiltration using 2% lidocaine
Study NCT01753921 — intervention group
Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
Study NCT01753921 — intervention group
Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
Study NCT01753921 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MRI study of the brain will be performed at t=3months.
Study NCT03434938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge.
Study NCT05717556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Jugular Vein Catheterization
Description: Inserting a cannula into the internal jugular vein
Study NCT01955954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canary Breathing System
Description: The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
Study NCT00276640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine, carboplatin
Description: vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
Study NCT00276640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine, carboplatin, etoposide
Description: vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10
Study NCT00276640 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks
Study NCT05959993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Care Model Based Nursing Interventions
Description: The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
Study NCT00914329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelsemium Sempervirens
Description: 5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study NCT00914329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelsemium Sempervirens
Description: 15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study NCT00914329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study NCT02070848 — intervention group
Intervention type: OTHER
Intervention: Session 5
Description: 2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
Study NCT03699709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Budgeting, purchasing and cooking educational intervention
Description: Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
Study NCT02002780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day Camp
Description: The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project.
Study NCT01338636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: 5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
Study NCT03316937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Types of scalers
Description: Scaling
Study NCT00540124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg once a day
Study NCT00540124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day
Study NCT00540124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.2 mg once a day
Study NCT03219840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Study NCT01046539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDC-0313 + Buprenorphine
Description: 1 and 4 mg (1 dose for each) + 8 mg
Study NCT01046539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg
Study NCT02164877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pectin
Description: Patients allocated to experiment group will receive 15g pectin each day
Study NCT02164877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pectin
Description: Patients allocated to experiment group will receive 15g pectin each day
Study NCT03599349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound w/ visualization
Study NCT01862705 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thoracic spine manipulation
Description: TSM thrust or non-thrust
Study NCT01862705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation
Description: TSM thrust or non-thrust
Study NCT00331643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT03369379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 Vitamin
Description: Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
Study NCT03369379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT01337895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dairy
Description: No more than 1 serving per day
Study NCT01337895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dairy
Description: 4 or more servings per day
Study NCT03278262 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Study NCT00504426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
Study NCT00504426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
Study NCT04791501 — intervention group
Intervention type: DEVICE
Intervention: Mechanical ventilation
Description: Ventilatory support
Study NCT01560039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
Study NCT01560039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: EEG neurofeedback based on the primary motor cortex
Study NCT01560039 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Sham EEG neurofeedback
Study NCT02605629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CG428
Description: The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
Study NCT02605629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
Study NCT02279043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction with users of IUC and non-IUC users
Description: Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users.
Study NCT02279043 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Interaction with non-IUC users only
Description: Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions.
Study NCT04739501 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: Trans-arterial chemoembolization in patients with hepatocellular carcinoma
Study NCT01866228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation Recording
Study NCT01922492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous islet transplantation
Description: Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization.
Study NCT01922492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anti-diabetic drugs
Description: * Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose.